Giving Life to Science®

We are dedicated to changing the treatment landscape for patients with devastating diseases

Unlocking the Potential of Validated Pharmacology

We do this by improving tolerability, enabling oral administration or enhancing on-target efficacy to unlock new classes of medicine

Strong track record of success has now generated

27 therapeutics and therapeutic candidates

17 are clinical stage

2 granted FDA clearance & European marketing authorization and a third that will soon be filed for FDA approval

Our network of scientific collaborators enables us to identify or co-invent key intellectual property before it's published in major journals

Our seasoned senior leadership team oversaw R&D of therapeutics supporting 26 regulatory approvals and served in the C-suite of companies acquired for more than $14B in aggregate

Publications
Internal Pipeline
PureTech's Lymphatic Leap
Gamma Delta T Cells Support Pancreatic Oncogenesis by Restraining αβ T Cell Activation

CD4(+) T regulatory cells (T(regs)), which express the Foxp3 transcription factor, play a critical role in the maintenance of immune homeostasis. Here, we show that in mice, T(regs) were most abundant in the colonic mucosa.

Full Article

Vedanta
Science: The Gut’s Clostridium Cocktail
Press releases
2022-08-09
PureTech to Receive up to Approximately $115.4 Million from Sale of a Portion of Founded Entity Shares
Press releases
2022-08-08
PureTech Founded Entity Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-2 Trial of KarXT in Schizophrenia
Press releases
2022-08-04
Notice of Half-Yearly Results